Payment overview · 2025
General Payments
$297.30
18 reported records · 8 companies
Healthcare provider profile · identity verified
Dorothy Breault, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CONCORDIA, KS · NPI 1245458256
Verified facts
What the public records show
CMS Open Payments records show Dorothy Breault, M.D. received $297.30 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.54 | 24.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.48 | 16.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.90 | 15.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.04 | 12.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.23 | 10.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.23 | 10.5% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.19 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.69 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $297.30 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.54 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.48 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.90 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
124 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 982 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 674 | 102 |
| Losartan Potassium | Losartan Potassium | 580 | 102 |
| Lisinopril | Lisinopril | 446 | 73 |
| Omeprazole | Omeprazole | 421 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 62 |
| Potassium Chloride | Potassium Chloride | 346 | 50 |
| Meloxicam | Meloxicam | 316 | 57 |
| Furosemide | Furosemide | 311 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 38 |
| Gabapentin | Gabapentin | 275 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 226 | 26 |
| Metformin Hcl Er | Metformin Hcl | 216 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 38 |
| Trazodone Hcl | Trazodone Hcl | 199 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 39 |
| Simvastatin | Simvastatin | 178 | 32 |
| Montelukast Sodium | Montelukast Sodium | 173 | 28 |
| Sertraline Hcl | Sertraline Hcl | 163 | 20 |
| Eliquis | Apixaban | 160 | 25 |
| Donepezil Hcl | Donepezil Hcl | 139 | 16 |
| Myrbetriq | Mirabegron | 130 | 15 |
| Ozempic | Semaglutide | 127 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 15 |
| Farxiga | Dapagliflozin Propanediol | 124 | suppressed |
| Glipizide | Glipizide | 124 | 17 |
| Famotidine | Famotidine | 120 | 19 |
| Prednisone | Prednisone | 118 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 12 |
| Lovastatin | Lovastatin | 113 | 20 |
| Mirtazapine | Mirtazapine | 105 | 16 |
| Pregabalin | Pregabalin | 105 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 16 |
| Buspirone Hcl | Buspirone Hcl | 90 | 13 |
| Carvedilol | Carvedilol | 90 | 11 |
| Metformin Hcl | Metformin Hcl | 90 | 15 |
| Spironolactone | Spironolactone | 90 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 23 |
| Allopurinol | Allopurinol | 83 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 19 |
| Digoxin | Digoxin | 75 | suppressed |
| Lorazepam | Lorazepam | 73 | 23 |
| Fentanyl | Fentanyl | 72 | suppressed |
| Bupropion Xl | Bupropion Hcl | 71 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 71 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 69 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Baclofen | Baclofen | 67 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 13 |
| Estradiol | Estradiol | 58 | 12 |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 57 | suppressed |
| Gemfibrozil | Gemfibrozil | 57 | suppressed |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Finasteride | Finasteride | 55 | suppressed |
| Jardiance | Empagliflozin | 54 | suppressed |
| Alprazolam | Alprazolam | 53 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 50 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Linzess | Linaclotide | 47 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 47 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 19 |
| Cefdinir | Cefdinir | 39 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 30 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Budesonide | Budesonide | 33 | suppressed |
| Nyamyc | Nystatin | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Mupirocin | Mupirocin | 25 | 11 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paroxetine Mesylate | Paroxetine Mesylate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $297.30 · 18 records | PFIZER INC. | ABRYSVO, AIRSUPRA, DALVANCE, EVENITY, Korlym, LEQVIO, Ozempic, PREVNAR 20, Rybelsus, SKYCLARYS, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error